Suicide gene therapy using reducible poly (oligo-d-arginine) for the treatment of spinal cord tumors

Biomaterials

Volumn 32, Issue 36, 2011, Pages 9766-9775

  Won, Young Wook ^a   Kim, Kyung Min ^a   An, Sung Su ^b   Lee, Minhyung ^a   Ha, Yoon ^b   Kim, Yong Hee ^a  

^a Hanyang University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Cancer gene therapy; Reducible polymer; Spinal cord tumor; Suicide gene therapy

Indexed keywords

CANCER GENE THERAPY; CENTRAL NERVOUS SYSTEMS; CLINICAL USE; GANCICLOVIR; HERPES SIMPLEX; IN-VIVO; LOCOMOTOR FUNCTION; NONVIRAL; NONVIRAL VECTORS; REDUCIBLE POLYMER; SPINAL CORDS; SUICIDE GENE THERAPY; THYMIDINE KINASE; TOXIC METABOLITES; TUMOR SUPPRESSION;

ARGININE; DISEASES; DOSIMETRY; ENZYMES; GENE EXPRESSION; GENETIC ENGINEERING; TUMORS; VIRUSES;

GENE THERAPY;

GANCICLOVIR; POLYMER; REDUCIBLE POLY(OLIGO DEXTRO ARGININE); THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD TUMOR; SUICIDE; SUICIDE GENE THERAPY;

ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MOTOR ACTIVITY; OXIDATION-REDUCTION; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS; SPINAL CORD; SPINAL CORD NEOPLASMS; THYMIDINE KINASE; TRANSFECTION;

RATTUS; SIMPLEXVIRUS;

EID: 80054071706     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.08.089     Document Type: Article

References (41)

1. Molina C.A., Gokaslan Z.L., Sciubba D.M. Spinal tumors. Primary central nervous system tumors 2011, Part 3: 529-547.
2. Sandu N., Pöpperl G., Toubert M.E., Spiriev T., Arasho B., Orabi M., et al. Current molecular imaging of spinal tumors in clinical practice. Mol Med 2011, 17:308-316.
3. Witham T.F., Khavkin Y.A., Gallia G.L., Wolinsky J.P., Gokaslan Z.L. Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol 2006, 2:87-94.
4. Kim J., Kim S.W., Kim W.J. PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy. Oligonucleotides 2011, 21:101-107.
5. Han S., Mahato R.I., Sung Y.K., Kim S.W. Development of biomaterials for gene therapy. Mol Ther 2000, 2:302-317.
6. Hedley D., Ogilvie L., Springer C. Carboxypeptidase G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer 2007, 7:870-879.
7. Vajda A., Marignol L., Foley R., Lynch T.H., Lawler M., Hollywood D. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients. Cancer Treat Rev 2011, 10.1016/j.ctrv.2011.03.003.
8. Rautsi O., Lehmusvaara S., Ketola A., Maatta A.M., Wahlfors J., Pellinen R. Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy. Cancer Gene Ther 2008, 15:303-314.
9. Faneca H., Faustino A., Pedroso de Lima M.C. Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes. J Control Release 2008, 126:175-184.
10. Xu F., Li S., Li X.L., Guo Y., Zou B.Y., Xu R., et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009, 16:723-730.
11. Rath P., Shi H., Maruniak J.A., Litofsky N.S., Maria B.L., Kirk M.D. Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr Stem Cell Res Ther 2009, 4:44-49.
12. Sharp J., Keirstead H.S. Stem cell-based cell replacement strategies for the central nervous system. Neurosci Lett 2009, 456:107-111.
13. Mello L.E., Longo B.M. Neurogenesis: a change of paradigms. Perspectives of stem cells 2010, 11-33. 10.1007/978-90-481-3375-8-2.
14. Canine B.F., Wang Y., Ouyang W., Hatefi A. Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus. J Control Release 2011, 151:95-101.
15. Garcia-Rodriguez L., Abate-Daga D., Rojas A., Gonzalez J.R., Fillat C. E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models. Gene Ther 2011, 18:73-81.
16. Bonini C., Bondanza A., Perna S.K., Kaneko S., Traversari C., Ciceri F., et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007, 15:1248-1252.
17. Schepelmann S., Springer C.J. Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 2006, 6:647-670.
18. Kim W., Kim S. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 2009, 26:657-666.
19. Jeong J.H., Kim S.W., Park T.G. Molecular design of functional polymers for gene therapy. Prog Polym Sci 2007, 32:1239-1274.
20. Won Y.-W., Lim K.S., Kim Y.-H. Intracellular organelle-targeted non-viral gene delivery systems. J Control Release 2011, 152:99-109.
21. Won Y.-W., Yoon S.-M., Lee K.-M., Kim Y.-H. Poly(oligo-d-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. Mol Ther 2011, 19:372-380.
22. Won Y.-W., Kim H.A., Lee M., Kim Y.-H. Reducible poly(oligo-d-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol Ther 2010, 18:734-742.
23. Manickam D.S., Li J., Putt D.A., Zhou Q.-H., Wu C., Lash L.H., et al. Effect of innate glutathione levels on activity of redox-responsive gene delivery vectors. J Control Release 2010, 141:77-84.
24. Kim P.-H., Kim T.-i., Yockman J.-W., Kim S.-W., Yun C.-O. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 2010, 31:1865-1874.
25. Kim T.-i., Kim S.W. Bioreducible polymers for gene delivery. React Funct Polym 2011, 71:344-349.
26. Hyun H., Won Y.W., Kim K.M., Lee J., Lee M., Kim Y.H. Therapeutic effects of a reducible poly (oligo-d-arginine) carrier with the heme oxygenase-1 gene in the treatment of hypoxic-ischemic brain injury. Biomaterials 2010, 31:9128-9134.
27. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995, 12:1-21.
28. Jeong J.H., Kim S.H., Christensen L.V., Feijen J., Kim S.W. Reducible poly(amido ethylenimine)-based gene delivery system for improved nucleus trafficking of plasmid DNA. Bioconjug Chem 2010, 21:296-301.
29. Männistö M., Reinisalo M., Ruponen M., Honkakoski P., Tammi M., Urtti A. Polyplex-mediated gene transfer and cell cycle: effect of carrier on cellular uptake and intracellular kinetics, and significance of glycosaminoglycans. J Gene Med 2007, 9:479-487.
30. Pichon C., Billiet L., Midoux P. Chemical vectors for gene delivery: uptake and intracellular trafficking. Curr Opin Biotechnol 2010, 21:640-645.
31. Ou M., Xu R., Kim S.H., Bull D.A., Kim S.W. A family of bioreducible poly(disulfide amine)s for gene delivery. Biomaterials 2009, 30:5804-5814.
32. Bauzon M., Jin F., Kretschmer P., Hermiston T. In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer. Gene Ther 2009, 16:1169-1174.
33. Lu Y., Madu C.O. Viral-based gene delivery and regulated gene expression for targeted cancer therapy. Expert Opin Drug Deliv 2010, 7:19-35.
34. Immonen A., Vapalahti M., Tyynela K., Hurskainen H., Sandmair A., Vanninen R., et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004, 10:967-972.
35. Paíno T., Gangoso E., Medina J.M., Tabernero A. Inhibition of ATP-sensitive potassium channels increases HSV-tk/GCV bystander effect in U373 human glioma cells by enhancing gap junctional intercellular communication. Neuropharmacology 2010, 59:480-491.
36. Pu K., Li S.-y., Gao Y., Ma L., Ma W., Liu Y. Bystander effect in suicide gene therapy using immortalized neural stem cells transduced with herpes simplex virus thymidine kinase gene on medulloblastoma regression. Brain Res 2011, 1369:245-252.
37. Cottin S., Ghani K., de Campos-Lima P.O., Caruso M. Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy. Mol Cancer 2010, 9:141-150.
38. Dachs G.U., Tupper J., Tozer G.M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005, 16:349-359.
39. Sandmair A.-M., Loimas S., Puranen P., Immonen A., Kossila M., Puranen M., et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000, 11:2197-2205.
40. Sobani Z.A., Quadri S.A., Enam S.A. Stem cells for spinal cord regeneration: current status. Surg Neurol Int 2010, 1:93-107.
41. Teng Y.D., Lavik E.B., Qu X., Park K.I., Ourednik J., Zurakowski D., et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci 2002, 99:3024-3029.